Published in:
01-02-2011 | Article selection
Correction: Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial
Published in: Critical Care | Issue 1/2011
Login to get accessExcerpt
After publication of our article [1], we noted typographical errors in our tables and in the labelling of Figure 3 (Figure 1). There have been no changes to the results or their interpretation.
Figure 1
Kaplan-Meier curve showing probability of survival during the first 28 days according to treatment group, among patients with sepsis. Dexmedetomidine decreased the probability of dying within 28 days by 70%; this beneficial effect was not seen in patients who were not septic (P value for interaction = 0.11 implying an interaction between sepsis and the treatment groups).
× ![]()
…